·
1 Min Read

AMA statement on FDA decision on naloxone nasal

AMA commends FDA’s approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose.

Press Releases
·
2 Min Read

AMA applauds FDA for requiring naloxone information on opioid labels

The new labeling can serve as a starting point for discussion between patients and physicians about risks and benefits associated with opioids.

Press Releases
·
5 Min Read

July 10, 2020: State Advocacy Update

AMA urges all states to follow Michigan effort to increase access to naloxone and more in the latest State Advocacy Update.

Advocacy Update
·
5 Min Read

Feb. 28, 2020: State Advocacy Update

Warning on naloxone in CO, prior authorization in ME and more in AMA's latest state advocacy efforts.

Advocacy Update
Naloxone injector.
·
2 Min Read

Lifesaving naloxone should be available almost everywhere

Publicly available naloxone rescue boxes could allow bystanders to save the lives of people experiencing opioid overdoses.

Behavioral Health
·
3 Min Read

AMA strengthens its policies promoting naloxone access and education

Physicians and medical students acted today to strengthen existing AMA policy promoting increased access to naloxone, the opioid overdose-reversing drug.

Press Releases
Elizabeth Salisbury-Afshar, MD, MPH
·
3 Min Read

Anyone can save a life with naloxone: What patients should know

The signs of an overdose, how to administer naloxone, and the toll of stigma covered by experts in a presentation at AMA’s Chicago headquarters.

Behavioral Health
·
4 Min Read

March 7, 2019: State Advocacy Update

State medical societies work to remove prior authorization for MAT, Massachusetts Insurance Commissioner's naloxone bulletin and more in AMA's state advocacy efforts.

Advocacy Update
·
4 Min Read

Jan. 24, 2019: National Advocacy Update

The FDA and naloxone access, firearm background checks, and more in AMA's latest national advocacy news.

Advocacy Update